# Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer

> **NCT05244434** · NA · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Advanced Breast Adenocarcinoma
- Advanced HER2-Negative Breast Carcinoma
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Hormone Receptor-Positive Breast Carcinoma
- Metastatic Breast Adenocarcinoma
- Metastatic HER2-Negative Breast Carcinoma
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8

## Interventions

- **OTHER:** Best Practice
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT05244434
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07-03
- **Primary completion:** 2023-01-26
- **Final completion:** 2023-01-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI withdrawn
- **Last updated:** 2022-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05244434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05244434, "Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05244434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*